Anemia of Chronic Kidney Disease
| Autor: | Sarah Tomasello |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Nephrology
medicine.medical_specialty Kidney business.industry Anemia medicine.medical_treatment Disease medicine.disease medicine.anatomical_structure Erythropoietin hemic and lymphatic diseases Internal medicine Medicine Pharmacology (medical) Renal replacement therapy Bone marrow business Intensive care medicine Kidney disease medicine.drug |
| Zdroj: | Journal of Pharmacy Practice. 21:181-195 |
| ISSN: | 1531-1937 0897-1900 |
| DOI: | 10.1177/0897190008315906 |
| Popis: | Chronic kidney disease may result in complete kidney failure and contribute to many other health issues. Anemia is a logical consequence of the disease because the kidneys are the primary source of erythropoietin, the hormone that acts to stimulate red blood cell production in the bone marrow. All patients with chronic kidney disease are at risk for anemia, and treating anemia is extremely important to their health and well-being. Preventing or reversing the effects of anemia on the heart may decrease morbidity and mortality and improve quality of life. Many patients fail to receive treatment for anemia before requiring renal replacement therapy for end-stage renal disease. Pharmacists can play a vital role in screening, evaluating, designing proper treatment regimens, and monitoring patients with anemia of chronic kidney disease. Current recommendations regarding anemia are reviewed, including evaluation, pharmacotherapeutic agents, monitoring parameters, and goals of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|